Comparaciones de ambos estudios en MA en red (network MA) no eran justificables dadas las diferencias en los diseños. Un estudio fase IV con problemas metodológicos como el PRAGUE 18 da una luz con respecto a la comparación, sin encontrar diferencias. http
RT @YndigegnY: Prasugrel vs Tica debate still going on this morning in the lab... now comparing the two studies... PRAGUE-18 https://t.co…
Prasugrel vs Tica debate still going on this morning in the lab... now comparing the two studies... PRAGUE-18 https://t.co/Bxc29UuebI ISAR-REACT5 https://t.co/9pmYvE7Ube https://t.co/T6TS2S0V7L
Prasugrel vs Ticagerol, different drugs, almost same results #UMKCRCT https://t.co/O8TlKKij1G.
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @krychtiukmd: Small study comparing Prasugrel and Ticagrelor after AMI found no differences reg. ischemic or bleeding endpoints #Cardio…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel... https://t.co/w8s5y6v0JR
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
No significant difference in outcomes between Prasugrel and Ticlagrelor after PCI for STEMI https://t.co/jAILhbGbsQ
PRAGUE-18: similar outcomes for ticagrelor vs prasugrel 1y after MI treated with PCI; and “economically-motivated” switches to clopidogrel appeared safe https://t.co/HkBWIKhwKE @JACCJournals
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
PRAGUE-18 + 1 year f/u shows no difference between prasugrel and ticagrelor. I’ll probably be switching to prasugrel only post MI (cost driven). Will you? @adrianocarlessi https://t.co/eVkkDIJfmQ
older inexpensive drugs are heard to beat https://t.co/wfLJrzJavH
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @accpcardprn: Battle of the P2Y12 Inhibitors in ACS: PRAGUE-18 one-year results https://t.co/HVgsglwHWU
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @accpcardprn: Battle of the P2Y12 Inhibitors in ACS: PRAGUE-18 one-year results https://t.co/HVgsglwHWU
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
RT @JACCJournals: Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC h…
Battle of the P2Y12 Inhibitors in ACS: PRAGUE-18 one-year results https://t.co/HVgsglwHWU
Economically motivated switch to clopidogrel from prasugrel or ticagrelor not assoc w/ increased ischemic events. #JACC https://t.co/M1knR7GLSD https://t.co/RiaNClJB4Y
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
Interesante estudio. Que aplica al país.@victor_moles https://t.co/dEaDDykKgo
RT @Office_j: 【PRAGUE-18試験1年観察データ:PCI施行AMI例に対するプラスグレル群とチカグレロル群の転帰に有意差なし】 https://t.co/TziARfliLA JACC
RT @drmkmittal: 🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Ve…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
Artigo publicado no @JACCJournals https://t.co/L8AUZa7uRR
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @gonzaeperez: Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos econ…
RT @krychtiukmd: Small study comparing Prasugrel and Ticagrelor after AMI found no differences reg. ischemic or bleeding endpoints #Cardio…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
Estudio PAGUE 18. Tica vs Prasu sin diferencias a 1 año en pacientes post #STEMI. 44 y 34% switch a clopi por motivos económicos. @SIAC_cardio @JACCJournals @jpcostabel @SAC_54 @fernando_wyss https://t.co/y6bPh2zhGn
RT @rafasadaba: Prasugrel and ticagrelor appear to be similarly effective during the first year following a myocardial infarction. https://…
RT @Borjaibanez1: Ticagrelor and prasugrel equal in patients presenting with STEMI. PRAGUE-18 is a unique trial comparing the 2 potent P2Y1…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
@JACCJournals 1-Year Outcomes of Patients Undergoing Primary Angioplasty for Myocardial Infarction Treated With Prasugrel Versus Ticagrelor https://t.co/eorHRaS15B
RT @Borjaibanez1: Ticagrelor and prasugrel equal in patients presenting with STEMI. PRAGUE-18 is a unique trial comparing the 2 potent P2Y1…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
Small study comparing Prasugrel and Ticagrelor after AMI found no differences reg. ischemic or bleeding endpoints #Cardiology #myocardialinfarction #heartattack #PCI https://t.co/fs8wsNhpfD https://t.co/wrShibfF1g
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @JACCJournals: What are the 1-year outcomes of prasugrel vs. ticagrelor in ACS patients treated with PCI? #JACC https://t.co/KfzGDcSUb3…
RT @GreggWStone: Markedly underpowered trial. False reassurance? Should underpowered trials be published in leading journals? What is their…
RT @drmkmittal: 🙏PRAGUE-18, Prasugrel=Ticagrelor for efficacy 1yr after MI. 💲motivated switch 2 plavix post DC, similar ischemic events. Ve…
Ticagrelor and prasugrel equal in patients presenting with STEMI. PRAGUE-18 is a unique trial comparing the 2 potent P2Y12inhib. Important study @JACCJournals @CNIC_CARDIO https://t.co/UA4RRSwgxO